Robert L. Capizzi

4.9k total citations
134 papers, 4.0k citations indexed

About

Robert L. Capizzi is a scholar working on Oncology, Molecular Biology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Robert L. Capizzi has authored 134 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 48 papers in Oncology, 38 papers in Molecular Biology and 31 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Robert L. Capizzi's work include Acute Lymphoblastic Leukemia research (31 papers), Acute Myeloid Leukemia Research (25 papers) and Cancer Treatment and Pharmacology (17 papers). Robert L. Capizzi is often cited by papers focused on Acute Lymphoblastic Leukemia research (31 papers), Acute Myeloid Leukemia Research (25 papers) and Cancer Treatment and Pharmacology (17 papers). Robert L. Capizzi collaborates with scholars based in United States, United Kingdom and France. Robert L. Capizzi's co-authors include Joseph R. Bertino, J. Courtland White, Bayard L. Powell, Robert E. Handschumacher, Seth A. Rudnick, Ed Cadman, Sue McIntosh, M. Robert Cooper, E Cadman and Roland T. Skeel and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Robert L. Capizzi

132 papers receiving 3.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Robert L. Capizzi United States 37 1.3k 1.2k 976 922 630 134 4.0k
T J McElwain United Kingdom 39 1.1k 0.9× 1.7k 1.4× 534 0.5× 1.5k 1.6× 747 1.2× 128 5.2k
Jon P. Gockerman United States 36 836 0.7× 1.5k 1.2× 574 0.6× 1.1k 1.2× 636 1.0× 128 4.4k
W. Wilmanns Germany 34 1.3k 1.0× 1.2k 1.0× 436 0.4× 1.8k 2.0× 439 0.7× 265 5.0k
E Frei United States 42 1.8k 1.4× 2.2k 1.8× 1.3k 1.4× 1.6k 1.7× 1.2k 1.9× 104 6.1k
M. Schneider France 38 1.0k 0.8× 2.8k 2.3× 420 0.4× 1.2k 1.3× 1.3k 2.0× 108 5.8k
F Zintl Germany 37 1.2k 0.9× 1.3k 1.1× 1.2k 1.2× 1.2k 1.3× 326 0.5× 161 4.1k
Irwin H. Krakoff United States 32 1.5k 1.2× 1.7k 1.4× 483 0.5× 388 0.4× 796 1.3× 124 4.5k
J C Drake United States 28 1.8k 1.4× 1.6k 1.3× 935 1.0× 560 0.6× 504 0.8× 51 4.3k
David D. Hurd United States 35 1.2k 0.9× 1.6k 1.3× 734 0.8× 2.4k 2.6× 457 0.7× 159 4.8k
Joseph H. Burchenal United States 34 1.3k 1.0× 1.3k 1.1× 1.1k 1.2× 622 0.7× 325 0.5× 147 4.3k

Countries citing papers authored by Robert L. Capizzi

Since Specialization
Citations

This map shows the geographic impact of Robert L. Capizzi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert L. Capizzi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert L. Capizzi more than expected).

Fields of papers citing papers by Robert L. Capizzi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert L. Capizzi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert L. Capizzi. The network helps show where Robert L. Capizzi may publish in the future.

Co-authorship network of co-authors of Robert L. Capizzi

This figure shows the co-authorship network connecting the top 25 collaborators of Robert L. Capizzi. A scholar is included among the top collaborators of Robert L. Capizzi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert L. Capizzi. Robert L. Capizzi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mok, Tony, Kazuhiko Nakagawa, Rafael Rosell, et al.. (2013). Phase 3 Randomized Study (ARCHER 1050) of 1st-Line Dacomitinib vs Gefitinib for Advanced NSCLC with EGFR Mutation(S). Annals of Oncology. 24. ix44–ix44. 4 indexed citations
2.
Rizzieri, David A., Harry P. Erba, M O’Donnell, et al.. (2008). Amonafide + ara-C in secondary acute myeloid leukemia (sAML): Consistent efficacy in poor risk populations. Journal of Clinical Oncology. 26(15_suppl). 7027–7027. 1 indexed citations
3.
Capizzi, Robert L., L Roman, S. Tjulandin, et al.. (2008). Phase II trial of C1311, a novel inhibitor of topoisomerase II in advanced breast cancer. Journal of Clinical Oncology. 26(15_suppl). 1055–1055. 25 indexed citations
4.
Chau, MyDoanh, et al.. (2007). Amonafide, a topoisomerase II inhibitor, is unaffected by P-glycoprotein-mediated efflux. Leukemia Research. 32(3). 465–473. 23 indexed citations
5.
Press, Oliver W., JM Vose, John Radford, et al.. (2001). Incidence of myelodysplastic syndromes (tMDS) and acute myeloid leukemia (tAML) in patients with low-grade non-Hodgkin's lymphoma (LG-NHL) treated with Bexxar (TM).. Blood. 98(1). 7 indexed citations
6.
Jeong, Yong Yeon, Donald G. Mitchell, Hie‐Won Hann, et al.. (2001). Hepatocellular Carcinoma After Systemic Chemotherapy: Gadolinium-Enhanced MR Measurement of Necrosis by Volume Histogram. Journal of Computer Assisted Tomography. 25(4). 624–628. 4 indexed citations
7.
Taylor, Charles W., et al.. (1996). Effects of amifostine and paclitaxel on growth of human ovarian carcinoma xenografts in the severe combined immune-deficient mouse: preliminary results.. PubMed. 23(4 Suppl 8). 35–9. 16 indexed citations
8.
Yang, Jin‐Long, Daniel Fernandes, Kenneth T. Wheeler, & Robert L. Capizzi. (1996). Pala enhancement of bromodeoxyuridine incorporation into DNA increases radiation cytotoxicity to human ovarian adenocarcinoma cells. International Journal of Radiation Oncology*Biology*Physics. 34(5). 1073–1079. 3 indexed citations
9.
Capizzi, Robert L., Björn Scheffler, Wolfgang Oster, Nassir Habboubi, & P S Schein. (1995). 577 Amifostine reduces cumulative cisplatin nephrotoxicity. European Journal of Cancer. 31. S123–S123. 3 indexed citations
10.
Yang, Jin‐Long, J. Courtland White, & Robert L. Capizzi. (1992). Modulation of the cellular pharmacokinetics of ara-CTP in human leukemic blasts by dipyridamole. Cancer Chemotherapy and Pharmacology. 29(3). 236–240. 3 indexed citations
11.
White, J. Courtland & Robert L. Capizzi. (1991). A critical role for uridine nucleotides in the regulation of deoxycytidine kinase and the concentration dependence of 1-beta-D-arabinofuranosylcytosine phosphorylation in human leukemia cells.. PubMed. 51(10). 2559–65. 45 indexed citations
12.
Wang, Liming, et al.. (1989). Determination of 3H-labelled cytosine arabinoside and eight metabolites in cell extracts by high-performance liquid chromatography and scintillation spectrometry. Journal of Chromatography B Biomedical Sciences and Applications. 491(2). 331–340. 7 indexed citations
13.
Peacock, James E., et al.. (1989). The safety of dental extractions in patients with hematologic malignancies.. Journal of Clinical Oncology. 7(6). 798–802. 33 indexed citations
14.
Chandrasekaran, B., et al.. (1987). Cross-resistance of menogaril and mitoxantrone in a subline of P388 leukemia resistant to doxorubicin.. PubMed. 71(2). 195–6. 6 indexed citations
15.
Capizzi, Robert L., et al.. (1983). Alteration of the pharmacokinetics of high-dose ara-C by its metabolite, high ara-U in patients with acute leukemia.. Journal of Clinical Oncology. 1(12). 763–771. 101 indexed citations
16.
Papac, Rose J., David R. Minor, Seth A. Rudnick, Lawrence R. Solomon, & Robert L. Capizzi. (1978). Controlled trial of methotrexate and Bacillus Calmette-Guérin therapy for advanced head and neck cancer.. PubMed. 38(10). 3150–3. 16 indexed citations
17.
Bertino, Joseph R., Barry Boston, & Robert L. Capizzi. (1975). The role of chemotherapy in the management of cancer of the head and neck: A review. Cancer. 36(S2). 752–758. 89 indexed citations
18.
Capizzi, Robert L., et al.. (1973). A table for the estimation of the spontaneous mutations rate of cells in culture. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis. 17(1). 147–148. 140 indexed citations
19.
Creasey, William A., et al.. (1972). Studies of the antineoplastic activity and metabolism of -(N)-heterocyclic carboxaldehyde thiosemicarbazones in dogs and mice.. PubMed. 32(3). 565–72. 40 indexed citations
20.
Creasey, William A., Robert L. Capizzi, & Ronald C. DeConti. (1970). Clinical and biochemical studies of high-dose intermittent therapy of solid tumors with hydroxyurea (NSC-32065).. PubMed. 54(3). 191–4. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026